JF
ACRS icon

Jump Financial’s Aclaris Therapeutics ACRS Stock Holding History

Jump Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,524
Closed -$24.8K – 1595
2024
Q2 		$24.8K Buy
+22,524
New +$26.5K ﹤0.01% 1702
2022
Q1 		– Sell
-32,000
Closed -$465K – 1504
2021
Q4 		$465K Buy
+32,000
New +$485K 0.03% 684
2021
Q3 		– Sell
-34,739
Closed -$609K – 1055
2021
Q2 		$609K Buy
+34,739
New +$789K 0.06% 407
2021
Q1 		– Sell
-10,800
Closed -$70K – 895
2020
Q4 		$70K Buy
+10,800
New +$45.6K 0.01% 888

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jump Financial's ACRS Position: Q3 2024 in Review

Jump Financial sold out of Aclaris Therapeutics (ACRS) in Q3 2024, closing a stake of 22,524 shares — an estimated $24.8K sold.

Jump Financial first reported a position in ACRS in Q4 2020 and held it in 4 quarters. The position peaked at $609K in Q2 2021. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

  • Jump Financial reported no remaining Aclaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jump Financial sold 22,524 Aclaris Therapeutics shares in Q3 2024, an estimated $24.8K.
  • Jump Financial first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 4 quarters.
  • Jump Financial's Aclaris Therapeutics position peaked at $609K in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on Jump Financial's 13F filing for Q3 2024, filed 14 Nov 2024.